Abstract: Disclosed herein implantable material and methods for treatment of growth plate injuries and other purposes. These materials can be particularly useful for treating children whose growth plates are active, and can help encourage proper healing and inhibit unwanted bone formations. Exemplary compositions can comprise poly (ethylene glycol) (“PEG”), gelatin (“GEL”), and heparin (“HEP”). The PEG, GEL, and HEP components can be present in various forms of these materials, such as methacrylated forms, etc. The implanted materials can be anti-osteogenic and/or ant-mineralization, and can help prevent unwanted bone growth in the implanted area, such as boney tethers, which can inhibit desirable growth plate healing and overall bone growth.

Abstract: Described herein are biomaterials, systems, and methods for guiding regeneration of an epiphyseal growth plate or similar interfacial tissue structures. In one aspect, the disclosed technology can include a biologic material that can comprise one or more of a hydrogel carrier for growth factors and MSCs, chondrogenic and immunomodulatory cytokines, microparticles for prolonged and spatially controlled growth factor delivery; and/or porous scaffold providing mechanical support. The implanted material can be applied via various different modalities depending on the nature of the physeal injury. One modality is an injectable hydrogel and another modality is an implantable hydrogel infused scaffold.

Abstract: Described herein are biomaterials, systems, and methods for guiding regeneration of an epiphyseal growth plate or similar interfacial tissue structures. In one aspect, the disclosed technology can include a biologic material that can comprise one or more of a hydrogel carrier for growth factors and MSCs, chondrogenic and immunomodulatory cytokines, microparticles for prolonged and spatially controlled growth factor delivery; and/or porous scaffold providing mechanical support. The implanted material can be applied via various different modalities depending on the nature of the physeal injury. One modality is an injectable hydrogel and another modality is an implantable hydrogel infused scaffold.

Abstract: The present disclosure provides an atomization device and an electronic cigarette. The atomization device includes a fluid tank, an atomization assembly arranged in the fluid tank, a first cover plate including first air inlet holes, and a second cover plate including second air inlet holes. The first air inlet holes are arranged along a first direction. The second air inlet holes are arranged along a second direction. The second cover plate is arranged on a bottom portion of the fluid tank. The second cover plate is connected with the first cover plate. The second cover plate is arranged between the fluid tank and the first cover plate. The first direction is different with the second direction. The first air inlet holes are configured to transmit gas to the second air inlet holes. The second air inlet holes are configured to transmit the gas into the fluid tank.

Abstract: Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and/or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.

Abstract: Described herein are biomaterials, systems, and methods for guiding regeneration of an epiphyseal growth plate or similar interfacial tissue structures. In one aspect, the disclosed technology can include a biologic material that can comprise one or more of a hydrogel carrier for growth factors and MSCs, chondrogenic and immunomodulatory cytokines, microparticles for prolonged and spatially controlled growth factor delivery; and/or porous scaffold providing mechanical support. The implanted material can be applied via various different modalities depending on the nature of the physeal injury. One modality is an injectable hydrogel and another modality is an implantable hydrogel infused scaffold.

Abstract: Methods of regenerating vital tooth tissue in situ after endodontic therapy include introducing a hydrogel scaffold into a root canal of a tooth in a patient after native pulp has been removed from the root canal. The hydrogel scaffold may comprise a sponge scaffold, and can be acellular. The hydrogel scaffold can contain chemotactic, angiogenic, neurogenic, and/or immunomodulatory biofactors that cause infiltration of endogenous cells from the patient into the root canal. Alternatively, such biofactors/drugs can be administered to the patient separately from the hydrogel scaffold. The hydrogel scaffold can fill the periapical space of an abscessed root.

Abstract: Methods and compositions are provided for modulating fat storage of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S, and especially cathepsin L. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that fat storage by the animal is reduced. The methods of the present invention can be used to diagnose obesity, diabetes and related diseases such as hyperinsulinmia, hyperglycermia, hypertension, cardiovascular diseases, muscular dystrophy and infertility, as well as to screen for agents that can be used therapeutics for these diseases.

Abstract: Methods and compositions are provided for modulating blood insulin levels of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S, and especially cathepsin L. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that the blood insulin level of the animal is reduced. The method can be used to treat hyperinsulinmia and related diseases such as insulin resistance, type II diabetes, and hyperglycermia.

Abstract: Methods and compositions are provided for modulating blood insulin levels of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S, and especially cathepsin L. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that the blood insulin level of the animal is reduced. The method can be used to treat hyperinsulinmia and related diseases such as insulin resistance, type II diabetes, and hyperglycermia.

Abstract: Methods and compositions are provided for modulating blood sugar levels of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S, and especially cathepsin L. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that the blood sugar level of the animal is reduced. The method can be used to treat diabetes, especially non-insulin-dependent (type II) diabetes mellitus (NIDDM) or maturity-onset diabetes mellitus.

Abstract: The invention provides a process for the living free radical addition polymerization of one or more ethylenically unsaturated monomers using at least one free-radical polymerization initiator and in the presence of one or more stable N-oxyl radicals, wherein at least one stable N-oxyl radical has polymerizable double bonds. The invention additionally provides polymers obtainable by this process, having a polydispersity index PDI of from 1.0 to 1.8, and provides for the use of stable N-oxyl radicals having polymerizable double bonds in the living free radical addition polymerization of one or more different ethylenically unsaturated monomers.